Form 4: Adicet Bio Director Jakobovits Receives Stock Options and Restricted Stock Units

Director Aya Jakobovits reports acquisition of stock options and restricted stock units in Adicet Bio, along with details of indirect beneficial ownership.

Summary

• Aya Jakobovits, a director of Adicet Bio, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On June 5, 2024, Jakobovits acquired 5,900 shares of common stock through Restricted Stock Units (RSUs) at $0.00.
• Jakobovits also acquired 26,400 stock options with an exercise price of $1.44, expiring on June 4, 2034.
• The RSUs and stock options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service on the board.
• Jakobovits also indirectly owns 356,343 shares through a trust for her daughter, 356,343 shares through a trust for her son, and 138,076 shares through a revocable trust with her spouse.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock options and RSU grants, which is neutral to slightly positive as it incentivizes management.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board of directors.

Future Outlook

The RSUs and stock options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, subject to continued service on the board.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule of the RSUs and stock options is typical for director compensation packages.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options positively, as it aligns the director's interests with the company's performance.
• The vesting schedule incentivizes the director to remain on the board and contribute to the company's success.

Key Dates